Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?

Abstract

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery was created to assess cognitive impairment in Alzheimer's disease (AD) but it is widely-used for various dementias. The aim of this study was to analyze the efficacy of using the CERAD battery in the assessment of patients with Parkinson's disease. Forty-nine patients with Parkinson's disease were divided into two groups (one with dementia and one without) using the Movement Disorder Society criteria for Parkinson's disease dementia. Cognitive deficits were assessed with the Clinical Dementia Rating Scale as the gold standard, and the CERAD. The ROC curve for the CERAD battery had an area under the curve = 0.989 (95% CI = 0.967 - 1, p<0.0001). Among the CERAD subtests, verbal fluency had the worst accuracy, and word list learning had the best accuracy. Despite the limits of this study, the CERAD battery can be efficient for assessment of cognitive deficits in Parkinson's disease patients.

Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

“…123 I-MIBG scintigraphy documenting cardiac sympathetic denervation is a supportive criterion for PD diagnosis, having over 80% specificity to distinguish PD from other parkinsonian conditions 21 . A study by Leite et al showed that this method identified cardiac sympathetic neurotransmission impairment in Brazilian de novo PD patients without clinically defined dysautonomia 50 . The DLB consortium criteria also classifies 123 I-MIBG as an indicative biomarker, showing good sensitivity (69%) and specificity (87%) values for discriminating probable DLB from probable AD 51 .…”

“…Um estudo prévio que realizou uma bateria neuropsicológica abrangente em pacientes com DP em lista de espera para implantação de estimulação cerebral profunda (ECP) demonstrou comprometimento cognitivo em 56,7% da casuística através da FAB, e em 76,7% pelo MoCA, destacando a importância de uma avaliação cognitiva formal neste grupo específico de pacientes candidatos a tal procedimento 48 . Da mesma forma, um estudo anterior demonstrou que a bateria neuropsicológica do Consórcio para Estabelecer um Registro para a Doença de Alzheimer (CERAD) poderia ser eficiente para avaliar déficits cognitivos em pacientes com DP 49 .…”

NIMHANS Neuropsychological Battery for Elderly in Parkinson’s Disease Patients: Validation and Diagnosis using MDS PD-MCI Task Force Criteria in Indian Population

“…[ 16 ] For level II assessments, comprehensive batteries such as International Parkinson and Movement Disorder Society (MDS) neuropsychological battery (NB) and The Consortium to Establish a Registry for Alzheimer’s disease (CERAD) neuropsychological battery were used. [ 17 18 ]…”

Divergence Between Informant and Self-Ratings of Activities of Daily Living Impairments in Parkinson’s Disease

“…Cognitive tests assigned to each domain were chosen according to the recommendations of the Movement Disorders Task Force (Litvan et al, 2012) and this comprehensive battery been previously used in a study with PD patients (Becker et al, 2020). The CERAD-PLUS battery has been shown to be accurate and useful in identifying cognitive impairment in PD patients (Karrasch et al, 2013;Camargo et al, 2018), while both the WIE [English version: Wechsler Adult Intelligence Scale (Yamawaki et al, 2020;Chen et al, 2021)] and the Leistungsprüfsystem 50 + batteries have been utilized in PD-cognition studies (Fengler et al, 2016;Kalbe et al, 2016). Furthermore, a recent systematic literature review identified specific tests used in PD research that have been normed for German-speaking populations and their corresponding cognitive domain (Liepelt-Scarfone et al, 2021).…”